跳至主要内容
临床试验/NCT00573521
NCT00573521已完成不适用

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

University of Pittsburgh1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2007年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
450
试验地点
1
主要终点
This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.

研究概览

简要总结

This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

详细描述

This is chart review at UPMC. NO human subject interaction will occur.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical information is collected by chart review of "case" and "control" patients.
  • A "case A" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.
  • A "case B" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam susceptible.
  • Additionally, 1 control patient in the hospital at the same time as the case patients will be randomly selected for each case and are not in either case group.

排除标准

  • Patients < 18 years of age

结局指标

主要结局

This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Brian Potoski

Assistant Professor

University of Pittsburgh

研究点 (1)

Loading locations...

相似试验